INTRODUCTION
Simple epithelia are composed of cohesive sheets of cells connected by tight junctions and polarized in an apical-basal orientation relative to an underlying basement membrane (Figure 1 ). The surrounding mesenchymal cells are embed ded within the interstitial extracellular matrix (ECM); lacking intercellular junctions, mesenchymal cells manifest primarily anterior-posterior polarity. 1,2 These structural differences are reflected in the characteristic genes each cell type expresses: epithelial cells express distinct junctional proteins (e.g. E-cadherin, also known as cadherin 1, type 1) and epithelial-specific cyto skeletal proteins (e.g. cyto keratins), whereas mesenchymal cells express N-cadherin (also known as cadherin 2 type 1) and mesenchymal-specific vimentin 3 (Box 1).
Desmoplasia, the appearance of fibrous, mesenchymal-like tissue in the peritumor stroma, is associated with poor clinical outcome. 4 Recent gene-profiling experiments suggest that the presence of a mesenchymal gene signature in tumors is predictive of poor clinical outcome in colorectal, breast and ovarian cancers. [5] [6] [7] [8] [9] [10] The principal cell types that contribute to the desmoplastic stromal reaction and mesenchymal gene signature are fibroblasts, which reside in the stroma and produce interstitial ECM molecules, and myofibroblasts, which produce growth factors, cytokines and ECM and also function to contract the ECM. Myofibroblasts have long been thought to be derived from fibroblasts, but recent data have shown that a substantial proportion of these cells are derived from epithelial-mesenchymal transition (EMT) associated with tumor progression, tissue fibrosis and other pathologies. 8 EMT involves fundamental changes in gene expression that disrupt epithelial polarity and establish a mesenchymal phenotype, with concomitant alterations in cyto skeletal organization, cell adhesion and production of ECM (Figure 2) . 1, 8, 11 This process of phenotypic conversion is well conserved throughout the Vertebrata, having emerged more than 500 million years ago. 11, 12 More recent observations have led to suggestions Epithelial-mesenchymal transition (EMT) is a phenotypic conversion that facilitates organ morphogenesis and tissue remodeling in physiological processes, such as embryonic development and wound healing. A similar phenotypic conversion is also detected in fibrotic diseases and neoplasia, and is associated with disease progression. EMT in cancer epithelial cells often seems to be an incomplete and bidirectional process. In this Review, we discuss the phenomenon of EMT as it pertains to tumor development, focusing on exceptions to the commonly held rule that EMT promotes invasion and metastasis. We also highlight the role of RAS-controlled signaling mediators, ERK1, ERK2 and phosphatidylinositol 3-kinase, as microenvironmental responsive regulators of EMT.
that EMT contributes to the phenotypic conversions observed in tissue fibrosis, 3,13-17 chronic inflammation 18 and rheumatic diseases, which are similar to conversions that occur in cancer progression. 1, 8, [19] [20] [21] [22] [23] Several recent reviews have summarized key signaling pathways involved in EMT and probed the link between the tumor microenvironment, fibrosis, EMT and cancer progression. 8, 24, 25 In this Review, we expand on these ideas by analyzing the mechanistic processes involved in this EMT conversion as part of the broader function of epithelial plasti city in tumor progression. We focus on the role of RAS signaling in epithelial tissue plasticity, because EMT in cancer is a dynamic and often incomplete process regulated by the micro environment and RAS. In addition, we review the role of RAS signaling effector pathways, most notably ERK1, ERK2 and phosphatidylinositol 3-kinase (PI3K)/AKT. Surprisingly, these pathways are responsive to the micro environment even when RAS is mutated into an activated form.
EMT IS AN INTRINSIC PLASTICITY OF TUMOR CELLS
When Boyer and colleagues studied cultured cells, 26 they first described EMT as a morphologic change from epithelial-like sheets of tumor cells to scattered, fibroblast-like cells capable of invading the basement membrane (Figure 3) . EMT has more recently been shown to occur during normal morphogenesis of the mammary gland and seems to be required for the formation of ducts. 27 Since the initial observations, EMT in cultured cancer cells has been characterized on the molecular level; altered gene-expression profiles, subcellular localization of protein and activity levels are now commonly used to identify EMT in cell culture (Table 1) . 3 EMT in cell culture can be either stable, that is the mesenchymal phenotype is sustained after the stimulus provoking the conversion is removed, or reversible, that is the cells revert, or undergo a mesenchymal-epithelial transition (MET), if the stimulus is removed. Experiments that quantitatively define the transient and incomplete phenotypic changes often observed in cultured tumor cells provide insight into the dynamic role EMT might have in neoplastic processes.
Insight into the complexity of EMT has been provided by studies that have used gene transcription and proteomic microarrays to assess EMT and MET. 28 Additional data suggest that the gene signatures of EMT and, more generally, plasticity of epithelial tumor cells are controlled by tissue and microenvironmental factors. 8 A comparison of transcriptional analyses of transforming growth factor (TGF) β1-induced EMT in EpH4 mouse mammary epithelial cells (transient EMT associated with a scattering phenotype) and EMT induced in EpH4 derivatives, such as c-Fos-ER-EpH4 (stable EMT without induction of malignancy) and RAS-EpH4 (stable EMT with induction of malignancy), revealed a common gene signature for EMT distinct from that associated with scattering, metastasis or oncogene expression ( Figure 4A ). Furthermore, a number of the genes in this signature have been linked to poor outcome in breast cancer. 28 Intriguingly, some changes in the gene-expression profile overlap with those documented to occur during epithelial-mesenchymal conversion of the medial edge epithelial seam in the embryonic palate. 29 Figure 4B and Table 2 show the extent of this overlap and compares the expression of genes that are upregulated by at least twofold during EMT of EpH4 mammary cells with those altered during EMT in the embryonic palate. 29 There are similar, but not identical, alterations in the expression of gene sets in EpH4 mammary cells and the embryonic palate. There is also an overlap between genes that are down regulated during EMT of EpH4 cells and alterations in the gene profile during palatogenesis: 70% of genes downregulated during EMT in EpH4 cells are altered by more than twofold during palato genesis (Table 3 ). The similarity between these two EMT signatures might result from the important role of TGF-β1 in driving mesenchymal conversion of both EpH4 cells 28 and the medial ridge epithelium of the embryonic palate. 29 Even though an EMT involves acquisition of at least some mesenchymal properties, the EMT-specific gene signature of EpH4 cells has surprisingly few gene-expression changes in common with stromal signatures. Such gene-expression changes include the fibroblast serum response that encompasses genes that are commonly upregulated in fibroblasts following serum stimulation in cell culture and which predicts poor outcome in breast and other cancers and enhances the prognostic value of an 'invasiveness' gene signature that is predictive of poor outcome in breast cancer. 6,17 A similarly limited overlap in altered gene expression is observed between the EMT-specific gene signature of EpH4 cells and the signatures of stromal tumors, such as head and neck squamous cell carcinoma 30 and prostate cancer 31 (Table 1) . Furthermore, the EMT-specific gene signature of EpH4 mammary cells bears little resemblance to an EMT-specific signature of head and neck squamous cell carcinoma 32 (Table 1) . Although these comparisons are limited, gene-signature analysis indicates that EMT is a process that is distinct from metastasis or tumorigenesis per se and could be tissue-specific and micro environmentspecific but has some resemblance to the embryonic process, at least when driven by a common factor, such as TGF-β1.
These studies illustrate that EMT in cancer is a complex process that seems to be a subset of an extensive phenotypic conversion program. 1, [33] [34] [35] [36] [37] The dynamic nature of interconversion of tumor phenotypes is more difficult to capture in vivo and has rarely been documented. Conversion of ductal epithelial cells of breast tumors into myoepithelial cells and myofibroblasts in vivo, however, is suggested by both the residual REVIEW expression of epithelial keratin markers in myoepithelial and myofibroblast cells and the simultaneous expression of myoepithelial (e.g. K14, K17 and vimentin) and myo fibroblast (e.g. vimentin and α-smooth muscle actin) markers. 38 Retention of some epithelial and myoepithelial markers in 'transdifferentiated' myofibroblasts and evidence of nonrandom X-chromosome inactivation patterns 38 also demonstrate epithelial plasticity towards the fibroblast phenotype. These results suggest that adult epithelial cells have a capacity to acquire aspects of a mesenchymal phenotype, and vice versa, in cell culture and breast cancer. The apparent rarity of an EMT in samples of human tumors probably reflects its transient nature and possible function as a brief pro invasion conversion program that is required for the colonization of distant tissues.
THE CLINICAL SIGNIFICANCE OF EMT
Although EMT has been clearly documented in cultured human cancer cell lines and some human tumors, its prevalence in aggressive tumors and role in clinical progression are still controversial. 33,39 A clear demonstration of EMT in most human neoplastic disease has been compromised by the cellular hetero geneity of most human tumors and by the lack of markers for mesenchymal and epithelial cells in solid tumor biopsies. Evidence that EMT might be highly localized and transient or limited to specific steps in metastatic colonization 32,40 further complicates clinical analysis of this process. Uncertainty regarding a clinical role for EMT in tumor progression is fueled by the rarity of morphologic changes in primary tumors observed by pathologists. Nonetheless, a number of studies have shown that expression of EMT-related genes (Box 1) 1,41 is associ ated with the metastatic/invasive phenotype. Furthermore, a recent study that compared the gene signature of metaplastic breast cancer with that of breast ductal carcinoma showed unique down regulation of epithelial genes and upregulation of mesenchymal genes in the metaplastic sample. 42 EMT might, therefore, be a feature of subtypes of breast carcinoma. These studies justify further assessment of EMT as an essential component of malignancy.
Nevertheless, increased expression of markers of EMT has been detected at the invasive fronts of aggressive tumors. 1 Numerous data illustrate an association between known regulators of EMT (e.g. Snail, Twist and Slug transcription factors) and both aggressive behavior of tumors in animal models and poor clinical outcome in patients with cancer, suggesting a role for EMT in tumor progression. 1, 23, 43 The pleiotropic nature of regulators of EMT, such as Snail, make it difficult to determine the extent to which they are causative of EMT in human cancer. 44 One approach used to detect diagnostic, tissuespecific markers of EMT is to identify alterations in gene expression associated with conversion in human tumors, animal models of cancer or cultured cells and then assess whether these gene signatures are correlated with clinical outcome. For example, such transcriptional profiling experiments resulted in the identification of a 'wound-responsive' gene signature 7 that predicts poor outcome in patients with breast cancer and increases the predictive value of other gene signatures associated with poor outcome in this disease. A similar approach identi fied key transcriptional alterations associated with the response of human breast epithelial cells to organotypic three-dimensional (3D) culture conditions that were also predictive of outcome in patients with breast cancer. 45 Although the prognostic value of EMT in breast cancer progression per se has to our knowledge not been reported, a number of genes in the EMT-metastatic gene signature of EpH4 mammary cells and gene signature of mammary tumor cells are associated with poor prognosis in breast cancer. 28 The EMT-specific gene signature of EpH4 mammary cells has limited overlap with two gene signatures of metastasis-invasion that predict poor clinical outcome in breast cancer ( Table 1) . 10, 46 More in-depth studies could help to clarify the clinical significance of EMT in tumor progression.
POSSIBLE FUNCTIONS OF EMT DURING TUMOR PROGRESSION
Numerous studies have shown that inhibiting the expression or impairing the function of EMTregulating factors blocks tumor migration and invasion in cultured epithelial cells. Invasion and metastasis of epithelial tumors, however, can occur in the absence of any detectible EMT and might not occur even in the presence of EMT. 1 For example, metastasis of some bladder cancer cell lines was associated with conversion to an epithelial phenotype (MET) rather than retention of the mesenchymal phenotype, 47 where as desmoid tumors are mesenchymal and locally invasive but do not metastasize. 48 EMT can be functionally uncoupled from the processes of invasion and metastasis. Conditional expression of TGF-β1 in mouse keratinocytes in the presence of a functional TGF-β1 receptor promoted EMT and metastasis in chemically induced papilloma; however, expression of a dominant-negative TGF-β1 receptor blocked the induction of EMT but did not influence the ability of TGF-β1 to promote metastasis. 49 Such observations indicate that it might be an over simplification to suggest that EMT is responsible only for increased migratory and invasive capacities.
A broader perspective on the role of EMT in cancer can be gleaned from the study of EMT in normal processes. Growing evidence suggests that EMT is integral to repair and renewal processes in normal tissue 50-53 and might contribute to fibrosis if these processes are sustained or otherwise aberrant. 1, 8, 15, 18, 54 As predicted by analysis of EMT gene signatures, EMT has been documented in migration of keratinocytes to wound sites 55 and in response to ultraviolet irradiation. EMT also occurs transiently at the tips of growing mouse mammary gland branches as they invade the fat pad during branching morphogenesis, 27 a process that resembles tumor invasion into adjacent tissues. In such instances, EMT-related processes co ordinate epithelial cell movement rather than dissemination.
Transient EMT in cancer can provide fibroblastlike properties to tumor cells, even in the absence of complete morphologic alteration. Several reports suggest that conversion of non-small cell lung carcinoma cells to a mesenchymal phenotype affects their sensitivity to mitogens and antiproliferative drugs. For example, EMT in non-small-cell lung carcinoma, which was detected by a mesenchymal gene signature, predicted a loss of response to activation of the EGFR and insensitivity to the EGFR inhibitor erlotinib. 56,57 Studies of experimental models have shown that acquisition of resistance to drugs, such as tamoxifen, is associated with, and might even promote, EMT. 58 These studies The dynamic role of EMT in mammary gland neoplastic processes. EMT during mammary tumor progression is postulated to facilitate invasion and colonization of distant tissues by tumor cells. EMT enables efficient penetration of vessels and escape into distant tissues, such as the lung or bone. A mesenchymal phenotype might be retained or revert to an epithelial phenotype (MET), depending on the tissue microenvironment. For example, some microenvironments, such as those provided by bones, can offer selective growth for a mesenchymal phenotype, whereas others (e.g. lung) might favor growth of an epithelial phenotype. Abbreviations: EMT, epithelialmesenchymal transition; MET, mesenchymal-epithelial transition.
demonstrated that EMT can be associated with changes in responsiveness to mitogens and antihormone therapy. It is unclear whether these effects are a direct or indirect consequence of phenotypic conversion. EMT could directly affect responses to mitogens and hormones as a result of altered expression of specific growth factor receptors, such as EGFR. Mesenchymal cells also differ from epithelial cells in their expression of transporters, and this could affect sensitivity to specific drugs. 59, 60 EMT might perform key immuno modulatory functions during tumor progression. For instance, fibroblasts possess immuno modulatory activities: they can permit leukocyte infiltration and retention within tissues at wound sites by presenting antigens to the immune system and by modifying T-cell responses. Fibroblasts could, therefore, function to mask tumor antigens and protect tumors from immune surveillance. 61 Fibroblasts produce and respond to a different set of cytokines and growth factors than epithelial cells and are more responsive to mitogenic and motogenic effects of platelet-derived growth factor (PDGF) and fibroblast growth factor than epithelial cells. These growth factors are abundant in the microenvironment of tissues undergoing extensive remodeling, as well as in tumors, and transiently or reversibly, EMT might facilitate growth of epithelial tumor cells in these types of dynamic micro environments. 62 Transient EMT enables epithelial cells to temporarily evade the effects of growth-inhibitory factors. Using a tissue micropatterning approach, Nelson and coauthors showed that a transient EMT occurred in regions of the lowest concentration of the branching inhibitor TGF-β1. 27 Transient EMT might provide the ductal cells with a temporary release from the inhibitory growth effects of TGF-β1 and enable response to other mitogens in the microenvironment. 63 In summary, the probable transient nature of EMT and paucity of mesenchymal markers for EMT have limited assessment of the extent to which this phenotypic conversion contri butes to tumor progression. Microdissection techniques that enable sampling of the tumor edge and improved imaging resolution in vivo will also contribute to clarification of the role of EMT in tumor metastasis.
MOLECULAR PATHWAYS THAT REGULATE EMT
Identification of the molecular pathways that regulate EMT in cancer cells has been the subject of intense investigation. 1,19,64-67 Although the processes involved in EMT have distinct characteristics in different tissues, RAS-regulated ERK1/ ERK2 and PI3K signaling pathways are increasingly recognized as key mediators of tumor cell plasticity. Gene signatures of deregulated RAS pathways are common in human tumors and, in addition to signatures of other oncogenic pathways, have enabled risk stratification in many types of human cancer. 68, 69 RAS proteins function as switches that are triggered by microenvironmental factors, such as growth factors and ECM molecules, and control many downstream signaling pathways. [70] [71] [72] Increased expression and/or mutation of RAS is a common early event in human tumors. 66, 71 In breast cancer, mutations that result in increased expression of RAS are more common than mutations that result in constitutive activation of RAS, 73 and increased activity of RAS-regulated downstream mediators, PI3K, ERK1/ERK2, is prognostic of a poor outcome. [74] [75] [76] [77] [78] [79] RAS-regulated pathways can induce autonomous, stable EMT in mammary epithelial cells. For example, exposing EpH4 cells with activating RAS mutations to TGF-β1 stimulates autocrine production of mesenchymal factors, such as PDGFA, PDGFB and PDGF receptors α and β, which maintain EMT even if exogenous TGF-β1 is withheld. In the absence of constitutively activated RAS signaling pathways in parental EpH4 mammary cells, TGF-β1 induces an incomplete and transient mesenchymal conversion that is reversible if TGF-β1 is removed. 80, 81 ERK1/ERK2 and PI3K-regulated pathways have central roles in EMT of tumor cells. PI3K stimulates proliferation, blocks apoptosis and promotes switching of cadherin isotypes on exposure to interstitial collagens; 65, 82 ERK1/ ERK2 disassemble adherens junctions and induce expression of mesenchymal ECM components, such as tenascin C, in addition to matrix metallo proteinases. 83, 84 Both pathways regulate the transcription factors Slug and Snail, which, in turn, promote EMT by suppressing expression of E-cadherin, genes encoding epithelial tight junc tion components and epithelialspecific cyto keratins; loss of E-cadherin induced by extra cellular matrix metallo proteinases can induce EMT as well. [85] [86] [87] Activation of the ERK1/ERK2 and PI3K pathways regulates the tumor-suppressive effects of environmental factors, such as TGF-β1, promoting growth and stabilization of EMT, 88 an effect that is achieved by linking TGF-β1 receptor activity to PI3K and ERK1/ERK2 signaling pathways. 28,49,80 RAS, PI3K and ERK1/ERK2 mediators are controlled through alteration of integrin-responsive signaling pathways: β1-integrins modulate the activity of growth factor receptors, such as the EGFR and PDGF receptor, which activate ERK1/ERK2 and PI3K signaling pathways. 89, 90 Additionally, the nuclear localization of activated ERK1/ERK2, which is required for its effects on gene tran scription, is regulated by hyaluronan. 91 Hence, ECM mol ecules and growth factors present in the tumor microenvironment control the locali zation and activation status of these RAS effectors, thereby determining the precise effect of these pathways on the behavior and differentiation or plasticity of tumor cells ( Figure 5 ).
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CONCLUSIONS
A more complete definition of how EMT contributes to cancer progression requires analysis of EMT during normal tissue renewal, development of mechanistic assays for in situ detection of EMT and continued identification of effectors of EMT that are prognostic for tumor outcome. RAS-regulated (ERK1/ERK2 and PI3K) signaling pathways are modulated by elements of the tumor microenvironment, suggesting functions beyond their well-studied roles in motility and proliferation. Another active field involves identification of regulatory pathways of EMT in the context of epithelial plasticity, to identify potential targets for therapy. In parallel, technical advances in accurate sampling and visuali zation of individual cells will enable isolation and analy sis of the key regulators of EMT in tumors. Microenvironmental and spatial regulation of signaling pathways controlling EMT. The RAS-ERK1/ERK2 pathway is an example of a signaling module that is responsive to microenvironmental cues and requires specific subcellular localization to determine the consequences of gene expression and tumor phenotype. A simplified version of this complex process is illustrated in the diagram. ECM components interact with integrin receptors at the cell surface (step 1) and the affinity of this interaction is modified by growth-factor-regulated signaling, in a process known as 'inside-out signaling' (steps 1-3). Conversely, the affinity of the integrin-ECM interaction affects growth-factor-regulated signaling, in a process known as 'outsidein signaling' (steps 2-3). The collective interactions between integrins and growth factor receptors promote the localization and activation of lipidmodified RAS (step 2) at the inner cell membrane leaflet (step 4). Activated RAS then selectively activates kinases, such as ERK1/ERK2 and other pathways, such as the PI3K/AKT pathway. RAS also blocks the tumorsuppressing activity of TGF-β1 by linking this pathway to ERK1/ERK2 signaling pathways (step 5). This linkage promotes the proinvasion properties of TGF-β1. Activated ERK1/ERK2 must translocate to the nucleus or celladhesion sites (known as 'focal contacts') to have access to target proteins that regulate EMT, motility and/or invasion. ERK1-regulated and ERK2-regulated gene expression (e.g. MMP9) further modifies the microenvironment of the tumor cell, thereby affecting the activation status of the integrin-growth factor receptor signaling pathway. This downstream consequence of RAS-ERK1-ERK2 activation and the reversal of steps 1-5 have profound effects on the phenotype even if other pathways are mutated. Abbreviations: AKT, protein kinase B; ECM, extracellular matrix; EMT, epithelial-mesenchymal transition; ERK1, extracellular signal-regulated kinase 1; ERK2, extracellular signal-regulated kinase 2; MMP, matrix metalloproteinase; PI3K, phosphatidylinoinositol 3-kinase; TGF, transforming growth factor. 
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